BLRX BioLineRx Ltd. gains 19% Apr 16, 2020

BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company's development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; and BL-9020 for the treatment of type 1 diabetes. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.http://www.priceseries.com/trade/BLRX-BioLineRx-Ltd-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2020040620200416.html